A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics

Table 2 Calculated systemic pharmacokinetic parameters for antibiotics and tazobactam assessed in this study compared with values reported for critically ill patients in the literature

	Population estimate in this study (and range in individuals)		Random effects – BSV (CV%)		Random error		Values reported in the literature
	CL, mL/minute	Vd	BSV_CL	BSV_Vd	RUV (CV%)	SD, mg/L	CL, mL/minute^a	Vd, L^a
Ciprofloxacin	58 (53-63)	37.7 L	10.0	34.6	-	0.99	34-617 [16-18]	28-224 [16-18]
Ciprofloxacin	58 (53-63)	(0.32-0.88 L/kg)	10.0	34.6	-	0.99	34-617 [16-18]	28-224 [16-18]
Meropenem	38 (23-95)	17.5 L	34.5	37.8	16.8	2.07	23-236 [10,19-27]	12-212 [10,19-27]
Meropenem	38 (23-95)	(0.14-0.61 L/kg)	34.5	37.8	16.8	2.07	23-236 [10,19-27]	12-212 [10,19-27]
Piperacillin	59 (37-115)	18.7 L	40.9	27.2	44	-	24-438 [10,21,28-34]	10-120 [10,21,28-34]
Piperacillin	59 (37-115)	(0.14-0.29 L/kg)	40.9	27.2	44	-	24-438 [10,21,28-34]	10-120 [10,21,28-34]
Tazobactam	113 (45-248)	49.3 L	52.3	34.5	41	-	22-180 [28-30,32,34]	8-60 [28-30,32,34]
Tazobactam	113 (45-248)	(0.54-0.55 L/kg)	52.3	34.5	41	-	22-180 [28-30,32,34]	8-60 [28-30,32,34]
Vancomycin	25 (16-33)	39.7 L	27.4	24.9	16	0.032	23-73 [35-37]	20-137 [35-37]
Vancomycin	25 (16-33)	(0.32-0.74 L/kg)	27.4	24.9	16	0.032	23-73 [35-37]	20-137 [35-37]

^aCalculated on the basis of the mean body weight reported in the study or using 70 kg, if required. BSV, between-subject variability; CL, clearance; CV, coefficient of variation; RUV, residual unexplained variability; SD, standard deviation; Vd, volume of distribution.

ISSN: 1364-8535